Evidence map›Paper›PMID 32258953›Full record

ArticleHepatology communications2020

Immune Checkpoint Axes Are Dysregulated in Patients With Alcoholic Hepatitis.

Wei Li, Ying Xia, Jing Yang, Haitao Guo, Guoqing Sun, Arun J Sanyal, Vijay H Shah, Yongliang Lou, Xiaoqun Zheng, Naga Chalasani and 1 more

Open access · goldAbstract read
In one paragraph

Article in Hepatology communications, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Wei LiDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Ying XiaDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Jing YangDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Haitao GuoDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Guoqing SunDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Arun J SanyalDivision of Gastroenterology and Hepatology Department of Medicine Virginia Commonwealth University Richmond VA.
Vijay H ShahDivision of Gastroenterology and Hepatology Mayo Clinic Rochester MN.ORCID https://orcid.org/0000-0001-7620-573X
Yongliang LouSchool of Laboratory Medicine Wenzhou Medical University Wenzhou China.
Xiaoqun ZhengDepartment of Clinical Laboratory the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University Wenzhou Zhejiang China.
Naga ChalasaniDivision of Gastroenterology and Hepatology Department of Medicine Indiana University School of Medicine Indianapolis IN.
Qigui YuDepartment of Microbiology and Immunology Indiana University School of Medicine Indianapolis IN.
Indiana University School of MedicineWenzhou Medical University · CNMayo Clinic in Arizona · USVirginia Commonwealth University · US

Funding

Alcohol's impact on immunological and virological profiles in HIV patientsUH2AA026218 · NIAAA · INDIANA UNIVERSITY INDIANAPOLIS · PI YU, QIGUI A. · 2017 to 2018
$318k
NIAAA NIH HHS UH2 AA026218
6 · The paper itself

Abstract

Alcoholic hepatitis (AH) is a severe inflammatory liver disease that develops in some heavy drinkers. The immune system in patients with AH is hyperactive and yet dysfunctional. Here, we investigated whether this immune-dysregulated state is related to the alcoholic impact on immune checkpoints (ICPs). We used multiplex immunoassays and enzyme-linked immunosorbent assay to quantify plasma levels of 18 soluble ICPs (sICPs) from 81 patients with AH, 65 heavy drinkers without liver diseases (HDCs), and 39 healthy controls (HCs) at baseline, 33 patients with AH and 32 HDCs at 6-month follow-up, and 18 patients with AH and 29 HDCs at 12-month follow-up. We demonstrated that baseline levels of 6 sICPs (soluble T-cell immunoglobulin and mucin domain 3 [sTIM-3], soluble cluster of differentiation [sCD]27, sCD40, soluble Toll-like receptor-2 [sTLR-2], soluble herpesvirus entry mediator [sHVEM], and soluble lymphotoxin-like inducible protein that competes with glycoprotein D for herpes virus entry on T cells [sLIGHT]) were up-regulated, while 11 sICPs (soluble B- and T-lymphocyte attenuator [sBTLA], sCD160, soluble cytotoxic T-lymphocyte-associated protein 4 [sCTLA-4], soluble lymphocyte-activation gene 3 [sLAG-3], soluble programmed death 1 [sPD-1], sPD ligand 1 [sPD-L1], sCD28, soluble glucocorticoid-induced tumor necrosis factor receptor-related protein [sGITR], sGITR ligand [sGITRL], sCD80, and inducible T-cell costimulator [sICOS]) were down-regulated in patients with AH compared to HDCs. The up-regulated sICPs except sLIGHT and down-regulated sCD80, sCD160, sCTLA-4, and sLAG-3 correlated positively or negatively with AH disease severity, bacterial translocation, and inflammatory factors. At follow-up, abstinent patients with AH still had higher levels of several sICPs compared to HDCs. We also compared expression of 10 membrane-bound ICPs (mICPs) on peripheral blood mononuclear cells (PBMCs) from patients with AH and HCs by flow cytometry and found that several mICPs were dysregulated on blood cells from patients with AH. The function and regulation of sICPs and mICPs were studied using PBMCs from patients with AH and HCs. Recombinant sHVEM affected tumor necrosis factor (TNF)-α and interferon-γ production by T cells from patients with AH and HCs.

Identifiers

PMID32258953
PMCPMC7109345
OpenAlexW3000020189

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.